Skip to content
DataLookout
Menu

NCT04141020

Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)

At risk: Primary completion moved 12 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 18 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Nov 1, 2026 to Nov 1, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 16 words
    • Enrollment closed, study ongoing
    • Final enrollment: 26 participants (planned 80)
    • Site details revised
  2. Minor Site contact updatedv21
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2021 to Oct 27, 2021
    • Site details revised
    v17
  4. Notable Start date: Sep 1, 2021 to Nov 1, 2021
    • Primary and study completion dates: Sep 1, 2026 to Nov 1, 2026
    v16
  5. Notable Start date: Aug 1, 2021 to Sep 1, 2021
    • Primary and study completion dates: Aug 1, 2026 to Sep 1, 2026
    v15
Show 12 earlier versionsHide 12 earlier versions
  1. Notable Start date: Jun 1, 2021 to Aug 1, 2021
    • Primary and study completion dates: Jun 1, 2026 to Aug 1, 2026
    v14
  2. Notable Start date: Apr 1, 2021 to Jun 1, 2021
    • Primary and study completion dates: Apr 1, 2026 to Jun 1, 2026
    v13
  3. Notable Start date: Jan 1, 2021 to Apr 1, 2021
    • Primary and study completion dates: Jan 1, 2026 to Apr 1, 2026
    v12
  4. Notable Start date: Dec 1, 2020 to Jan 1, 2021
    • Primary and study completion dates: Dec 1, 2025 to Jan 1, 2026
    v11
  5. Notable Start date: Oct 1, 2020 to Dec 1, 2020
    • Primary and study completion dates: Oct 1, 2025 to Dec 1, 2025
    v10
  6. Notable Start date: Sep 1, 2020 to Oct 1, 2020
    • Primary and study completion dates: Sep 1, 2025 to Oct 1, 2025
    v9
  7. Notable Start date: Aug 1, 2020 to Sep 1, 2020
    • Primary and study completion dates: Aug 1, 2025 to Sep 1, 2025
    v7
  8. Notable Start date: Jun 1, 2020 to Aug 1, 2020
    • Primary and study completion dates: Jun 1, 2025 to Aug 1, 2025
    v6
  9. Notable Start date: May 1, 2020 to Jun 1, 2020
    • Primary and study completion dates: May 1, 2025 to Jun 1, 2025
    v5
  10. Notable Start date: Apr 1, 2020 to May 1, 2020
    • Primary and study completion dates: Apr 1, 2025 to May 1, 2025
    • Collaborators expanded, about 8 words
    • Study arms: 4 to 2
    v4
  11. Notable Start date: Mar 1, 2020 to Apr 1, 2020
    • Primary and study completion dates: Mar 1, 2025 to Apr 1, 2025
    v3
  12. Notable Start date: Jan 1, 2020 to Mar 1, 2020
    • Primary and study completion dates: Jan 1, 2025 to Mar 1, 2025
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in gene expression from control arteries.
Timeframe: Day 18
Change in gene expression between blood samples.
Timeframe: Day 18
Change in gene expression.
Timeframe: Day 18

Arms and interventions

Microsurgical Clipping Treated with SirolimusExperimental

Participants undergoing standard of care microsurgical clipping of unruptured cerebral aneurysm will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to surgery.

Endovascular Treatment Treated with SirolimusExperimental

Participants undergoing standard of care endovascular treatment of unruptured cerebral aneurysm procedure will be treated with 2 mg Sirolimus daily for 14-18 consecutive days prior to procedure.

Procedures: Microsurgical clipping, Endovascular treatment

Drugs: Sirolimus

Sites

1 site in 1 country

  • University of MiamiMiami, Florida, United States